Alvotech arrived at 2026 with the story reduced to one facility: a Reykjavik plant that a year of FDA scrutiny had put at the center of everything. Its first three U.S. applications drew Complete Response Letters, the stock fell from a September 2025 high near $9 to a June 2026 low under $3, and the company spent the winter reworking the plant, its quality systems, and, in effect, its operating rhythm. Q1 2026 is the quarter that shows both the cost of that decision and why management was willing to pay it. Reported revenue fell roughly 20% to $105.9 million, because the facility improvements deliberately slowed production while license revenue actually rose. Against that, the company still booked a small profit. What the quarter did not provide was cash: operating cash flow turned negative by $60.4 million and cash fell to $63.8 million - which is why the follow-on equity raise and term-loan drawdown that landed in June and July matter as much as the income statement.
The central question this quarter answers is sequencing. Management decided that a clean, resubmittable package mattered more than a smooth quarter: dose the plant down, fix the observations, and resubmit the Biologics License Applications with a file that would not bounce. Q1 shows the down. The up is meant to come in 2026 - the company guides to $650–700 million of revenue and $180–220 million of adjusted EBITDA for the year, a step up from 2025's $588.9 million and $137.2 million. What decides the thesis is whether the regulatory clock, not the calendar, delivers. The FDA closed its May 2026 inspection with a Voluntary Action Indicated classification on July 29; the BLA resubmissions and a new Entyvio biosimilar application sit on that same path. Investors at roughly $4, with a market capitalization near $1.6 billion, are paying for the recovery to prove itself in approvals and launch revenue, not for a quarter that burned cash to build it.